Ceccarelli M, Venanzi Rullo E, Marino MA, d’Aleo F, Pellicanò GF, D’Andreaet F, et al. Non-AIDS defining cancers: a comprehensive update on diagnosis and management. Eur Rev Med Pharmaco. 2020;24:3849–75. https://doi.org/10.26355/eurrev_202004_20852.
Shiels MS, Islam JY, Rosenberg PS, Hall HI, Jacobson E, Engels EA, et al. Projected cancer incidence rates and burden of incident cancer cases in HIV-infected adults in the United States through 2030. Ann Intern Med. 2018;168:866–73. https://doi.org/10.7326/M17-2499.
Article PubMed PubMed Central Google Scholar
Di Benedetto F, De Ruvo N, Berretta M, Masetti M, Montalti R, Di Sandro S, et al. Don’t deny liver transplantation to HIV patients with hepatocellular carcinoma in the highly active antiretroviral therapy era. J Clin Oncol. 2006;24:e26–7. https://doi.org/10.1200/JCO.2006.06.1374.
Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59–67. https://doi.org/10.1016/S0140-6736(07)61050-2.
Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148:728–36. https://doi.org/10.7326/0003-4819-148-10-200805200-00005.
Alfa-Wali M, Tait D, Allen-Mersh T, Tekkis P, Nelson M, Stebbing J, et al. Colorectal cancer in HIV positive individuals: the immunological effects of treatment. Eur J Cancer. 2011;47:2403–7. https://doi.org/10.1016/j.ejca.2011.06.036.
Coghill AE, Shiels MS, Suneja G, Engels EA. Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol. 2015;33:2376–83. https://doi.org/10.1200/JCO.2014.59.5967.
Article PubMed PubMed Central Google Scholar
Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12:492–9. https://doi.org/10.1038/ni.2035.
Article CAS PubMed Google Scholar
Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974–82. https://doi.org/10.1200/JCO.2014.59.4358.
Article CAS PubMed PubMed Central Google Scholar
Zou WP, Wolchok JD, Chen LP. PD-L1 (B7–H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4. https://doi.org/10.1126/scitranslmed.aad7118.
Article CAS PubMed PubMed Central Google Scholar
Persad GC, Little RF, Grady C. Including persons with HIV infection in cancer clinical trials. J Clin Oncol. 2008;26:1027–32. https://doi.org/10.1200/JCO.2007.14.5532.
Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15:893–900. https://doi.org/10.1038/nm.1972.
Article CAS PubMed PubMed Central Google Scholar
Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis. 2013. https://doi.org/10.1093/infdis/jis630.
Article PubMed PubMed Central Google Scholar
Cockerham LR, Jain V, Sinclair E, Glidden DV, Hartogenesis W, Hatano H, et al. Programmed death-1 expression on CD4+ and CD8+ T cells in treated and untreated HIV disease. AIDS. 2014;28:1749–58. https://doi.org/10.1097/QAD.0000000000000314.
Article CAS PubMed Google Scholar
Zhang JY, Zhang Z, Wang XC, Fu JL, Yao JX, Jiao YM, et al. PD-1 up-regulation is correlated with HIV-specificmemory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressos. Blood. 2007;109:4671–4618. https://doi.org/10.1182/blood-2006-09-044826.
Article CAS PubMed Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026.
Article CAS PubMed Google Scholar
Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases. N Engl J Med. 2018;378:1029–41. https://doi.org/10.1056/NEJMra1615896.
Article PubMed PubMed Central Google Scholar
Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123:187–94. https://doi.org/10.1002/ijc.23487.
Article CAS PubMed Google Scholar
Karwacz K, Bricogne C, MacDonald D, Arce F, Bennett CL, Collins M, et al. PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol Med. 2011;3:581–92. https://doi.org/10.1002/emmm.201100165.
Article CAS PubMed PubMed Central Google Scholar
Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–42. https://doi.org/10.1111/j.1600-065X.2010.00923.x.
Article CAS PubMed PubMed Central Google Scholar
Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol. 2007;8:1246–54. https://doi.org/10.1038/ni1515.
Article CAS PubMed Google Scholar
Lurain K, Ramaswami R, Mangusan R, Widell A, Ekwede I, George J, et al. Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma. J Immunother Cancer. 2021;9:e002097. https://doi.org/10.1136/jitc-2020-002097.
Article PubMed PubMed Central Google Scholar
Gonzalez-Cao M, Martinez-Picado J, Karachaliou N, Rosell R, Meyerhans A. Cancer immunotherapy of patients with HIV infection. Clin Transl Oncol. 2019;21:713–20. https://doi.org/10.1007/s12094-018-1981-6.
Article CAS PubMed Google Scholar
Cook MR, Kim C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. JAMA Oncol. 2019;5:1049–54. https://doi.org/10.1001/jamaoncol.2018.6737.
Gonzalez-Cao M, Morán T, Dalmau J, Garcia-Corbacho J, Bracht JWP, Bernabe R, et al. Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study. JAMA Oncol. 2020;6:1063–7. https://doi.org/10.1001/jamaoncol.2020.0465.
Article PubMed PubMed Central Google Scholar
Bari S, Muzaffar J, Chan A, Jain SR, Haider AM, Curry MA, et al. Outcomes of programmed cell death protein 1 (PD-1) and programmed death-ligand 1(PD-L1) inhibitor therapy in HIV patients with advanced cancer. J Oncol. 2019. https://doi.org/10.1155/2019/2989048.
Article PubMed PubMed Central Google Scholar
Wang CY, Liu J, Lei H, Li Y, Wu J, Guo BL, et al. Clinical characteristics and outcomes of newly diagnosed patients with HIV-associated aggressive B-cell NHL in China. J Cell Mol Med. 2022;26:5067–77. https://doi.org/10.1111/jcmm.17534.
Article CAS PubMed PubMed Central Google Scholar
Dittus C, Grover N, Sethi T, Cohen JB, Voloschin A, Rabadey J, et al. A multicenter, real-world analysis of primary central nervous system lymphoma in those with and without human immunodeficienc virus. EJHaem. 2022;3:734–8. https://doi.org/10.1002/jha2.474.
Article PubMed PubMed Central Google Scholar
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39. https://doi.org/10.1056/NEJMoa1507643.
Article CAS PubMed PubMed Central Google Scholar
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35. https://doi.org/10.1056/NEJMoa1504627.
Article CAS PubMed PubMed Central Google Scholar
Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–84. https://doi.org/10.1016/S1470-2045(15)70076-8.
Article CAS PubMed Google Scholar
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30. https://doi.org/10.1056/NEJMoa1412082.
Article CAS PubMed Google Scholar
Gane E, Verdon DJ, Brooks AE, Gaggar A, Nguyen AH, Subramanian GM, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. J Hepatol. 2019;71:900–7. https://doi.org/10.1016/j.jhep.2019.06.028.
Article CAS PubMed Google Scholar
Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. 2006;12:1198–202. https://doi.org/10.1038/nm1482.
留言 (0)